SubHero Banner
Text

Olumiant® (baricitinib) – Emergency use authorization expansion

July 28, 2021 - Eli Lilly announced the emergency use authorization (EUA) approval of Olumiant (baricitinib), for the treatment of suspected or laboratory confirmed coronavirus disease 2019 (COVID-19) in hospitalized adults and pediatric patients two years of age or older requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).

Download PDF